We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Meningococcal B Vaccine Could Improve Protection Against Gonorrhea
News

Meningococcal B Vaccine Could Improve Protection Against Gonorrhea

Meningococcal B Vaccine Could Improve Protection Against Gonorrhea
News

Meningococcal B Vaccine Could Improve Protection Against Gonorrhea

Credit: Karolina Grabowska/ Pexels
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Meningococcal B Vaccine Could Improve Protection Against Gonorrhea"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Researchers at The University of Adelaide have found that the meningococcal B vaccine could improve protection against gonorrhoea in addition to protection against meningococcal B meningitis. 


This significant finding, in a joint study with the Women’s and Children’s Hospital, coincides with a rise in gonorrhoea cases globally and increasing bacterial resistance to drugs used to treat the infection.


Led by 2022 South Australian of the Year, University of Adelaide Professor of Vaccinology, and Women’s and Children’s Hospital Senior Medical Practitioner Helen Marshall AM, the observational study found that two doses of the meningococcal B vaccine were 33 per cent effective against gonorrhoea in adolescents and young adults.


Professor Marshall said the research aims to reduce not only gonorrhoea infection, but also the long-term effects of gonorrhoea, including infertility, pelvic inflammatory disease and blindness in babies born to infected mothers.

“With more than 106 million cases of gonorrhoea worldwide, and increasing at a rapid rate... it is vital that we explore new and improved measures to battle this infection."Professor Helen Marshall AM

“With more than 106 million cases of gonorrhoea worldwide, and increasing at a rapid rate, the issue is firmly on the World Health Organisation’s agenda,” Professor Marshall said.


“This research will feed into WHO’s vaccine roadmap to evaluate the evidence about the ability of vaccines to prevent gonorrhoea. Traditionally, treatment for gonorrhoea has relied on antibiotics, but as these have become increasingly less effective due to antibiotic resistant strains, it is vital that we explore new and improved measures to battle this infection.


“In South Australia, where we have a state-funded meningococcal B (MenB) vaccine program for infants, children and adolescents since 2019, we have been able to observe that its effectiveness against gonorrhoea in adolescents is about 33 per cent. Two years after introduction of the state-funded MenB vaccine program, we are already observing high effectiveness against meningococcal B disease and also moderate effectiveness in preventing gonorrhoea.


“The unprecedented scale of South Australia’s MenB vaccination programme offers valuable real-world evidence of the vaccine’s effectiveness against meningococcal B meningitis in children and adolescents, and gonorrhoea in adolescents and young people. This information is vital to inform global meningitis vaccination programmes and policy decisions.”


Left unchecked, gonorrhoea can spread to the blood and cause disseminated gonococcal infection (DGI). DGI is usually characterised by arthritis, tenosynovitis, and/or dermatitis and, ultimately, the condition can be life threatening. Professor Marshall’s research has been published in The Lancet Infectious Diseases  journal.


Reference: Wang B, Giles L, Andraweera P, et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect Dis. 2022. doi: 10.1016/S1473-3099(21)00754-4

  

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement